02269 WUXI BIO
- 14.060
- -0.500-3.43%
WUXI BIO News
Passed! Pharmacovigilance waited for an 8-year buffer period, and the company quickly responded
The new version of the US Biosafety Act (H.R. 8333) (hereinafter referred to as the “Act”) has ushered in the latest developments.
The 40-1 ratio is huge! The new version of the US House of Representatives “Biosafety Act” was passed in a hearing. The industry suggests paying attention to the subsequent run-in between the two house versions of the bill
① At the US House of Representatives hearing, the new version of the “Biosafety Act” was passed with a 40-1 vote; ② Compared with the previous version, the new bill made adjustments in the exemption period for existing contracts/products; at the same time, the companies involved clearly added pharmacological agents; ③ industry experts believe that rapid decoupling is not in the interests of the US industry; next, we need to focus on the run-in between the two houses of law.
Wuxi Biologics (Cayman) Maintains It Is Not a Security Threat After House Bill Changes; Stocks Drop 3%
According to a Friday filing on the Hong Kong bourse, Wuxi Biologics (Cayman) (HKG:2269) welcomed some of the changes made to the revised version of the Draft Bill (H.R.8333) held by the U.S. House Co
Hong Kong Stock Afternoon Review | The three major indices rose, and TechNet stocks strengthened, Ali rose nearly 7%; some domestic housing stocks rose, and Sunac China rose more than 9%
Photovoltaic solar energy stocks weakened, Follett Glass fell nearly 9%, and Xinyi Solar fell more than 8%; insurance stocks generally rose; China Taibao rose more than 2%, and China Life Insurance rose nearly 2%.
Express News | Pharmacobiology: It has neither a human genomics business nor does it collect human genomic data in any of its global businesses
Correction to WuXi Companies Article
U.S. companies until 2032 to work with Chinese biotech firms named in the bill. "WuXi Companies Shares Have Likely Priced in Outcome of U.S. House Committee Session -- Market Talk," at 0457 GMT, incor
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
The biotechnology sector of Hong Kong stocks weakened, with Zaiding Pharmaceuticals falling more than 6%, Pharmaceutical Kangde falling more than 5%, and Pharmaceutical Biotech and Zhaoyan New Pharmaceutical falling.
May 14 Repurchase Collection | HSBC Holdings, Pharmaceutical Biotech, etc. bought back one after another, of which HSBC Holdings spent HK$219 million
According to documents disclosed by the Hong Kong Stock Exchange on May 16, $HSBC Holdings (00005.HK) $ and $Pharmaceutical Biotech (02269.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.2 million common shares on May 14, involving an amount of HK$219 million. The repurchase price per share ranged from HK$69.15 to HK$68.2. ② $HSBC Holdings (00005.HK) $ repurchased 3.2 million common shares on May 13, involving an amount of HK$217 million. The repurchase price per share ranged from HK$68 to HK$67.5. ③ $medicine
Express News | US House of Representatives hearing votes to pass the new version of the “Biosafety Act”
Futu Morning Post | NASDAQ hits a new closing high, WSB concept stocks are booming; Powell: The Federal Reserve needs to “wait patiently”
All of the Qiaoshui and Gao Lin position reports were released; Ali fell more than 6%, and adjusted net profit fell 11% year over year; Google launched a new version of the search engine with generative AI functions.
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Pharmaceutical Biotech (02269) spent about HK$398.632 million to buy back 2.75,000 shares on May 14
Yao Ming Biotech (02269) issued an announcement and spent about HK$398.632 million to return it on May 14, 2024...
Hong Kong Stock Afternoon Review | Tech Index rose nearly 1%, TechNet stocks and biotech stocks rose higher, Bilibili rose more than 6%, and Laikai Pharmaceuticals rose more than 12%
Auto stocks rose more than 6%; Great Wall Motor rose more than 6%; NIO and Zero Sports Auto rose more than 5%; many coal stocks fell sharply, Yankuang Energy fell more than 6%, and Shougang resources fell nearly 6%.
Intraday Overview | Tech Index rose more than 1%, and TechNet stocks were trending strongly. Bilibili rose more than 6%; Tencent Music rose more than 9% after its performance
Technology Network stocks rose collectively, with Bilibili up more than 6%, Kuaishou and Xiaomi Group up more than 3%; auto stocks improved, Great Wall Motor rose more than 7%, NIO rose nearly 6%, and Zero Sports Auto rose nearly 5%.
Big Bank Rating | Jefferies: The upward potential of Pharmaceutical Biotech is greater than the downward potential rating “buy”
Glonghui, May 14 | Jefferies released a report saying that the current stock price of HK$14.7 for Pharmaceutical Biotech means that it only values existing non-US contracts, that is, it does not value existing US contracts, nor does it value new contracts in any region in the future. As unresolved issues will be resolved, the situation is even more clear. The bank believes that the upward potential of Yao Ming Biotech is greater than the downside potential, and that the company is the only large CRO/CDMO company with a market account ratio of only 1.4 times, while the price-earnings ratio of domestic peers is 2 to 3 times, and global peers are 4 to 5 times higher. The bank's target price for Medicinal Biotech was reduced from HK$53
The CXO sector of the Hong Kong stock market showed positive performance, Pharmaco-Ming Kangde rose more than 7%
Glonghui, May 14 | Yao Ming Kangde rose more than 7%, Pharmaceutical Biotech rose nearly 6%, and Cansino Biotech and Zhaoyan New Pharmaceutical followed suit.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
May 13 Repurchase Collection | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$217 million
According to HKEx disclosure documents on May 14, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.1976 million common shares on May 10, involving an amount of HK$217 million. The repurchase price per share ranged from HK$68.15 to HK$67.8. ② $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 13, involving an amount of HK$32.698,700. The repurchase price per share ranged from HK$109.4 to HK$10
Featured announcements | Tencent Music's adjusted net profit increased by 23.9%; King's Rui: Legendary Biotech's net loss narrowed
China Life Insurance: The cumulative original premium income for the first 4 months was about 371.2 billion yuan, an increase of 3.9% over the previous year; China Resources Land: The cumulative contract sales amount for the first 4 months was approximately RMB 72.0 billion.
Pharmaceutical Biotech (02269) spent HK$31.967 million to buy back 2.261,000 shares on May 13
Pharmaceutical Biotech (02269) issued an announcement to spend HK$31.967 million on May 13, 2024 to repurchase 2...
Analysis
Price Target
No Data
